---
title: "Teijin says Japan grants Xeomin approval for cervical dystonia, blepharospasm indications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290273226.md"
description: "Japan's Ministry of Health, Labour and Welfare has granted approval for the expanded use of XEOMIN (incobotulinumtoxinA) to treat cervical dystonia and blepharospasm. This regulatory clearance adds two new indications to the product's label in Japan, where it has been marketed since December 2020 under a license from Merz Therapeutics. The decision supports Teijin Limited's neurology portfolio."
datetime: "2026-06-19T07:00:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290273226.md)
  - [en](https://longbridge.com/en/news/290273226.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290273226.md)
generator: "portal-rs"
---

# Teijin says Japan grants Xeomin approval for cervical dystonia, blepharospasm indications

-   Japan’s MHLW cleared expanded use of XEOMIN (incobotulinumtoxinA) for cervical dystonia, blepharospasm, supporting Teijin’s neurology portfolio. \* Decision adds two indications to the product’s Japan label, where it has been marketed since December 2020 under a Merz Therapeutics license. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief via Business Wire (Ref. ID: 202606190300BIZWIRE\_USPR\_\_\_\_\_20260618\_BW047396) on June 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [3401.JP](https://longbridge.com/en/quote/3401.JP.md)

## Related News & Research

- [Teijin (TSE:3401) Following Its Rally Is The Valuation Upside Still There](https://longbridge.com/en/news/291042566.md)
- [10:19 ETUnited Vein & Vascular Centers Expands Tampa Bay Network With New South Tampa Vein Clinic](https://longbridge.com/en/news/296801788.md)
- [St Joseph subsidiary Fastbase AI prepares beta launch of global business search platform](https://longbridge.com/en/news/296792561.md)
- [Fujitsu, Tokyu Construction, and Kitano Construction launch field trial for AI that supports construction process management and risk reduction](https://longbridge.com/en/news/296939100.md)
- [Asahi Kasei says Japan approves Empaveli for C3 glomerulopathy, immune complex MPGN](https://longbridge.com/en/news/296747787.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**